InMode MD
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, InMode MD sits in the top decile of US sponsors by registered trial count (#696 of 15,742 sponsors by registered trial count).
InMode MD: 22 sponsored US clinical trials, 3 recruiting.
InMode MD sponsors 22 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 19 completed. The most-studied condition in this pipeline is Premature Jowl and Neck Laxity Following Facialplasty, with 1 trials.
Top-decile sponsor footprint
InMode MD ranks in the top decile of sponsors by registered trial count (#696 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
19 of 19 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
22 total, page 1 of 1
Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women
NCT07209397
Safety and Efficacy of Radio Frequency for the Treatment of Mild to Severe Inflammatory Acne
NCT05830968
Evaluation of Safety and Efficacy of Morpheus8 Applicator for the Treatment of Focal Hyperhidrosis of the Axillae Using Radio Frequency
NCT05860972
Transvaginal Radiofrequency Ablation for Overactive Bladder
NCT06458556
RF Microneedling With Multi-Depth Targeting Per Insertion for The Treatment of Cellulite
NCT06283056
Clinical Evaluation of Fractional Bi-Polar Radio-Frequency for Symptoms of Vulvovaginal Atrophy
NCT05398172
Bi-Polar Radio-Frequency and Electrical Muscle Stimulation for Symptoms of Mixed Urinary Incontinence (MUI)
NCT05287490
Clinical Evaluation of Fractional Bi-Polar RF for Symptoms of SUI and Vulvovaginal Atrophy
NCT04705571
Trim II for Noninvasive Lipolysis and Circumference Reduction of Abdomen.
NCT05398159
Treatment With the Evoke System for Facial and Submental Laxity
NCT04719013
Evaluation of the Evoke Radiofrequency Device for Improvement of Skin Appearance
NCT04721600
Retrospective Chart Review Study of Patients Treated With Votiva Device
NCT04437680
Retrospective Evaluation of Cellulite of Laxity Treatment Using Body Tite
NCT04419454
Radio Frequency (Forma Eye) Treatment for Dry Eye Disease Due to Meibomian Gland Dysfunction
NCT04120584
Safety and Efficacy of Combined EMS and RF Treatments
NCT04124419
Evoke Radiofrequency Device for Improvement of Skin Appearance
NCT04050033
Energy-Based Lower Eyelid Rejuvenation - Proof of Concept for InMode AccuTite With or Without Morpheus8
NCT04103619
The Use of RF in Premature Jowl and Neck Laxity Following Facialplasty
NCT03945422
Evaluate the Effect of Abdominal Electrical Muscle Stimulation on Abdominal Wall Restoration in Post - Partum Women
NCT03917160
Clinical Evaluation of CelluTite Treatment
NCT03769649
Clinical Evaluation of RFAL of Breast Envelope and NAC Position
NCT03863834
RF Rejuvenation for Pelvic Floor and Vagina
NCT03536819
Therapeutic Areas
What is open in the InMode MD pipeline
3 recruiting of 22 indexed (14% open); 19 completed (86%).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: Premature Jowl and Neck Laxity Following Facialplasty (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
InMode MD: open-pipeline peers nationwide
Peers matched on 22 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
InMode MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 22 trials (± recruiting share)
- Alaunos Therapeutics · 22 trials · 0% recruiting
- Alexza Pharmaceuticals · 22 trials · 0% recruiting
- Calithera Biosciences · 22 trials · 0% recruiting
- Fate Therapeutics · 22 trials · 14% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Rigel Pharmaceuticals · 14% recruiting · 22 trials
- Reproductive Medicine Associates of New Jersey · 14% recruiting · 51 trials
- Beth Israel Deaconess Medical Center · 14% recruiting · 488 trials
- Case Comprehensive Cancer Center · 14% recruiting · 407 trials
Related
What to do with this InMode MD page
22 registered trials is a research-attention snapshot, not an endorsement of InMode MD or any single study.
- 3 of InMode MD's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Premature Jowl and Neck Laxity Following Facialplasty is the condition InMode MD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Premature Jowl and Neck Laxity Following Facialplasty trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
InMode MD pipeline card: 22 registered trials from official public datasets.Report a data error.